An open-label, two-part study to characterize the pharmacokinetics of a single intravenous dose of pazopanib (GW786034) and the absorption, distribution, metabolism and elimination of a single oral [14C] labeled dose of pazopanib in subjects with solid tumor malignancies.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Pazopanib; Pazopanib
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Status changed from active, no longer recruiting to completed.
- 05 Jun 2008 The expected completion date for this trial is now 1 Jul 2008 as reported by ClinicalTrials.gov.
- 05 Jun 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.